Wire · opportunities
Oneness Biotech Advances SNS851 to Phase 1 Multiple-Ascending Dose Evaluation for ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 September 2026 · Fusion42 review
Oneness Biotech has completed the single ascending dose phase of its Phase 1 trial for SNS851, an siRNA therapy targeting obesity-associated metabolic diseases, and is moving to the multiple ascending dose phase with results expected in Q1 2027. SNS851 targets energy metabolism rather than appetite suppression, potentially offering a novel approach or complement to existing GLP-1 therapies.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 29 Sep 2026 and 30 Sep 2026.
◆ ◆ The Wire takeaway
Your metabolic drug development just opened a new route beyond appetite suppression. You can now explore combining this siRNA approach with GLP-1 treatments to widen clinical benefits and differentiate your offering.
◆ Coverage
3 sources · first reported 29 Sep 2026 · latest 30 Sep 2026
◆ Related on Wire
◆ Topics